- Home
- SSL vs VKTX Comparison
SSL vs VKTX Comparison
Compare SSL & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSL
- VKTX
- Stock Information
- Founded
- SSL 1950
- VKTX 2012
- Country
- SSL South Africa
- VKTX United States
- Employees
- SSL N/A
- VKTX N/A
- Industry
- SSL Oil & Gas Production
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SSL Energy
- VKTX Health Care
- Exchange
- SSL Nasdaq
- VKTX Nasdaq
- Market Cap
- SSL 2.9B
- VKTX 3.1B
- IPO Year
- SSL N/A
- VKTX 2015
- Fundamental
- Price
- SSL $5.04
- VKTX $30.82
- Analyst Decision
- SSL
- VKTX Buy
- Analyst Count
- SSL 0
- VKTX 12
- Target Price
- SSL N/A
- VKTX $84.00
- AVG Volume (30 Days)
- SSL 1.4M
- VKTX 3.9M
- Earning Date
- SSL 01-01-0001
- VKTX 07-23-2025
- Dividend Yield
- SSL N/A
- VKTX N/A
- EPS Growth
- SSL N/A
- VKTX N/A
- EPS
- SSL N/A
- VKTX N/A
- Revenue
- SSL $13,819,021,376.00
- VKTX N/A
- Revenue This Year
- SSL N/A
- VKTX N/A
- Revenue Next Year
- SSL $2.76
- VKTX N/A
- P/E Ratio
- SSL N/A
- VKTX N/A
- Revenue Growth
- SSL N/A
- VKTX N/A
- 52 Week Low
- SSL $2.78
- VKTX $18.92
- 52 Week High
- SSL $8.40
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- SSL 54.90
- VKTX 65.63
- Support Level
- SSL $5.07
- VKTX $29.76
- Resistance Level
- SSL $5.30
- VKTX $32.10
- Average True Range (ATR)
- SSL 0.14
- VKTX 1.62
- MACD
- SSL 0.01
- VKTX 0.49
- Stochastic Oscillator
- SSL 72.00
- VKTX 91.22
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: Southern Africa Energy & Chemicals business; and International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Geographically the company generates the majority of its revenue from South Africa.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.